Table 3. Expression of APM in GBM CSC and FBS tumor cell lines.
| Cell line | Molecule* | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HLA | β2-m† | HLA class II | LMP | TAP1 | TAP2 | ||||
| A | A HC‡ | 2 | 7 | 10 | |||||
| 0627 CSCs | 2 (76) | 4 (23) | 2 (49) | 1 (6) | 4 (100) | 2 (100) | 1 (6) | 1 (1) | 1 (4) |
| 0627 FBS | 2 (80) | 2 (33) | 2 (61) | 2 (45) | 3 (98) | 2 (99) | 1 (3) | 1 (3) | 3 (53) |
| 080125 CSCs | 1 (4) | 3 (94) | 2 (100) | 1 (8) | 6 (100) | 2 (98) | 1 (2) | 1 (6) | 1 (5) |
| 080125 FBS | 2 (81) | 4 (63) | 4 (98) | 1 (6) | 6 (100) | 3 (86) | 2 (87) | 1 (3) | 2 (87) |
| 080418 CSCs | 2 (78) | 1 (5) | 1 (3) | 2 (72) | 2 (98) | 2 (95) | 1 (3) | 1 (3) | 1 (3) |
| 080418 FBS | 1 (6) | 3 (24) | 2 (94) | 1 (2) | 3 (100) | 2 (100) | 1 (4) | 1 (1) | 1 (4) |
| 080201 CSCs | 14 (99) | 16 (99) | 7 (87) | 6 (71) | 14 (99) | 12 (100) | 3 (99) | 3 (98) | 6 (99) |
| 080201 FBS | 7 (98) | 37 (98) | 53 (98) | 6 (78) | 20 (100) | 12 (97) | 5 (96) | 4 (98) | 7 (99) |
| 071011 CSCs | 7 (80) | 26 (93) | 10 (43) | 6 (22) | 36 (99) | 15 (88) | 3 (45) | 2 (60) | 9 (88) |
| 071011 FBS | 5 (78) | 7 (98) | 20 (98) | 2 (98) | 8 (99) | 3 (95) | 1 (5) | 1 (6) | 2 (97) |
| 080325 CSCs | 10 (98) | 19 (99) | 9 (99) | 12 (99) | 24 (100) | 20 (100) | 4 (78) | 4 (89) | 7 (99) |
| 070104 CSCs | 1 (2) | 1 (3) | 2 (45) | 2 (76) | 1 (4) | 1 (3) | 1 (2) | 1 (3) | 1 (3) |
| 1869 EBV-B | 16 (96) | 19 (91) | 19 (98) | 10 (94) | 5 (82) | 6 (99) | 3 (89) | 4 (91) | 8 (94) |
Note: Values are indicated as ratio between the mean of fluorescence intensity of cells stained with the selected mAb and that of the negative control; bold values indicate significant MRFI (≥ 2). The numbers in parenthesis represent the percentage of positive cells. The experiment has been repeated thrice; SD for each value ≥ 0.6 ≤ 4.
*
Expression of APM molecules was evaluated by intracellular staining of permeabilized cells and cytofluorimetric analysis.
†
β-2 Microglobulin.
‡
β-2 Microglobulin–free HLA-A heavy chain.